Therefore, CCAT2 could be considered a valuable pan-cancer biomarker that is associated with a more aggressive disease course, one with potential as a therapeutic target of new treatments or for use in strategies for overcoming chemoresistance and radioresistance [136,137,138]. This evidence concerns the gene CCAT2 and cancer.